Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $694,000.

  • Allogene Therapeutics' Capital Expenditures fell 60.14% to $171,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $643,000, marking a year-over-year increase of 2.06%. This contributed to the annual value of $694,000 for FY2024, which is 54.22% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Capital Expenditures is $694,000, which was down 54.22% from $1.5 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Capital Expenditures ranged from a high of $66.0 million in FY2020 and a low of $694,000 during FY2024.
  • For the 3-year period, Allogene Therapeutics' Capital Expenditures averaged around $2.5 million, with its median value being $1.5 million (2023).
  • In the last 5 years, Allogene Therapeutics' Capital Expenditures grew by 29.86% in 2020 and then crashed by 75.80% in 2022.
  • Over the past 5 years, Allogene Therapeutics' Capital Expenditures (Yearly) stood at $66.0 million in 2020, then tumbled by 67.49% to $21.4 million in 2021, then slumped by 75.80% to $5.2 million in 2022, then plummeted by 70.80% to $1.5 million in 2023, then slumped by 54.22% to $694,000 in 2024.